Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - TD Cowen raised its price target on Tempus AI Inc (NASDAQ:TEM) to $72.00 from $62.00 on Wednesday, while maintaining a Buy rating on the stock. The company, now valued at $11.5 billion, has seen its shares surge 19.5% in the past week alone.
The firm cited stronger genomic volumes and a positive outlook for the company’s Ambry business as key factors behind the increased target.
TD Cowen noted that Tempus AI delivered improved performance in its genomics segment during the second quarter, prompting the analyst to raise volume growth projections for this business line.
The firm also elevated its outlook for Tempus AI’s Ambry business, expecting continued market share gains and growth, albeit at levels below what was seen in the second quarter.
While Tempus AI’s data revenues and growth exceeded expectations in the second quarter, TD Cowen observed that the company’s guidance implies slower growth in the second half of the year, leading the firm to reduce its estimates for that period.
In other recent news, Tempus AI Inc. reported its second-quarter 2025 earnings, which exceeded revenue forecasts. The company achieved a revenue of $314.6 million, surpassing the anticipated $297.8 million, and reported a narrower-than-expected loss per share of -$0.22, compared to the forecast of -$0.25. These results indicate a stronger performance than analysts had projected. Additionally, Stifel has maintained its Hold rating on Tempus AI stock, with a price target set at $65. This decision reflects the firm’s ongoing coverage and analysis of the company’s financial health. These developments offer investors insights into Tempus AI’s current financial standing and analyst perspectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.